- Home
- EDRY vs INMB Comparison
EDRY vs INMB Comparison
Compare EDRY & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | INMB |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 64.7M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EDRY | INMB |
|---|---|---|
| Price | $60.79 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.33 | $7.00 |
| AVG Volume (30 Days) | 182.9K | ★ 313.1K |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | $40.95 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $11.95 | $1.09 |
| 52 Week High | $73.07 | $2.60 |
Technical Indicators
Market Signals| Indicator | EDRY | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 39.25 |
| Support Level | $17.86 | $1.36 |
| Resistance Level | $73.07 | $2.46 |
| Average True Range (ATR) | 6.40 | 0.10 |
| MACD | -0.46 | -0.03 |
| Stochastic Oscillator | 50.24 | 14.29 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.